Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | UBE2M | P61081 | 2/20 | 0.31 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24365738 | 1.00 | NPC1 (0.36) | NPC1RAB9AMEN1KMT2AUBE2M | |
| SCHEMBL29081416 | 1.00 | NPC1 (0.36) | NPC1RAB9AMEN1KMT2AUBE2M | |
| SCHEMBL30514949 | 0.94 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL25322543 | 0.94 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL25322537 | 0.94 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL25324407 | 0.93 | NPC1 (0.34) | NPC1RAB9AKMT2AUBE2MDCUN1D1 | |
| SCHEMBL30551016 | 0.93 | NPC1 (0.34) | NPC1RAB9AKMT2AUBE2MDCUN1D1 | |
| SCHEMBL25334175 | 0.92 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL25334173 | 0.92 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL30470291 | 0.92 | NPC1 (0.33) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | NPC1 24/4885RAB9A 420/4885MEN1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.